var data={"title":"Famciclovir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Famciclovir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6178?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">see &quot;Famciclovir: Drug information&quot;</a> and <a href=\"topic.htm?path=famciclovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Famciclovir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169842\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Famvir [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169843\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Famciclovir;</li>\n      <li>Ava-Famciclovir;</li>\n      <li>CO Famciclovir;</li>\n      <li>Famvir;</li>\n      <li>PMS-Famciclovir;</li>\n      <li>Sandoz-Famciclovir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052683\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiviral Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052677\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">see &quot;Famciclovir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes simplex virus (HSV) genital infection: </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immunocompetent patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial episode: Children weighing &ge;45 kg and Adolescents: Oral: 250 mg 3 times daily for 7 to 10 days (CDC [Workowski 2015]; <i>Redbook</i> [AAP 2015]). <b>Note:</b> Treatment can be extended if healing is incomplete after 10 days of therapy (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Recurrence: Adolescents: <b>Note:</b> Initiate treatment within 1 day of lesion onset or during the prodrome that precedes some outbreaks (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">One-day regimen: Oral: 1,000 mg twice daily for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Two-day regimen: Oral: 500 mg once as a single dose, followed 12 hours later by 250 mg twice daily for a total of 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Five-day regimen: Oral: 125 mg twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Suppressive therapy: Adolescents: Oral: 250 mg twice daily. <b>Note:</b> Duration not established; efficacy/safety have been demonstrated for 1 year (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive patients: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial or recurrent episodes: Adolescents: Oral: 500 mg twice daily for 5 to 10 days (HHS [OI adult 2016]). <b>Note:</b> Treatment can be extended if healing is incomplete after 10 days of therapy (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic suppressive therapy: Adolescents: Oral: 500 mg twice daily; suppressive therapy can be continued indefinitely regardless of CD4 count in patients with severe recurrences of genital herpes or in patients who want to minimize frequency of recurrences, or to reduce the risk of genital ulcer disease in patients with CD4 cell counts &lt;250 cells/mm<sup>3</sup> who are starting antiretroviral therapy. However, continuation of therapy should be reviewed annually, particularly if immune reconstitution has occurred (HHS [OI adult 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes labialis/orolabial (cold sores) in HIV-exposed/-positive patients, treatment:</b> Limited data available: Adolescents: Oral: 500 mg twice daily for 5 to 10 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes zoster (shingles) in HIV- exposed/-positive patients, treatment </b>(HHS [OI adult 2016]): Limited data available: Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acute localized dermatomal lesion: </i>500 mg 3 times daily for 7 to 10 days; consider longer duration if lesions heal slowly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extensive cutaneous lesion or visceral involvement</i>: Initial therapy with acyclovir IV may be switched to famciclovir 500 mg 3 times daily to complete a 10- to 14-day course, when formation of new lesions has ceased and signs and symptoms of visceral VZV infection are improving</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Varicella infection (chickenpox) in HIV-exposed/-positive patients (uncomplicated cases), treatment:</b> Limited data available: Adolescents: Oral: 500 mg 3 times daily for 5 to 7 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Genital herpes simplex virus (HSV) infection:</b> Oral: <b>Note:</b> Initiate therapy as soon as possible after diagnosis and within 72 hours of rash onset.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immunocompetent patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial episode: 250 mg 3 times daily for 7 to 10 days. <b>Note:</b> Treatment can be extended if healing is incomplete after 10 days of therapy (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Recurrence:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer&rsquo;s labeling: 1,000 mg twice daily for 1 day. <b>Note:</b> Initiate therapy as soon as possible and within 6 hours of symptoms/lesions onset.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: 125 mg twice daily for 5 days or 500 mg as a single dose, followed by 250 mg twice daily for 2 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Suppressive therapy: 250 mg twice daily. <b>Note:</b> Duration not established, but efficacy/safety have been demonstrated for 1 year (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-infected patients:</i> Recurrent episodes: 500 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes labialis/orolabial (cold sores), recurrent episodes:</b> <b>Note:</b> Initiate therapy as soon as possible after diagnosis and within 72 hours of rash onset.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immunocompetent patients: </i>Oral: 1,500 mg as a single dose; initiate therapy at first sign or symptom such as tingling, burning, or itching (initiated within 1 hour in clinical studies)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV patients</i>: Oral: 500 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Herpes zoster (shingles), treatment:</b> Immunocompetent patients: Oral: 500 mg every 8 hours for 7 days<b> Note:</b> Initiate therapy as soon as possible after diagnosis and within 1 week of rash onset or any time before full crusting of lesions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Herpes zoster:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: Administer 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 59 mL/minute: Administer 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 39 mL/minute: Administer 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Administer 250 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Penciclovir (active metabolite) removed by hemodialysis; Administer 250 mg after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recurrent genital herpes: Treatment (single day regimen):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: Administer 1,000 mg every 12 hours for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 59 mL/minute: Administer 500 mg every 12 hours for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 39 mL/minute: Administer 500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Administer 250 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Penciclovir (active metabolite) removed by hemodialysis; administer 250 mg as a single dose after dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recurrent genital herpes: Suppression:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;40 mL/minute: Administer 250 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 39 mL/minute: Administer 125 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Administer 125 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Penciclovir (active metabolite) removed by hemodialysis; administer 125 mg after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recurrent herpes labialis: Treatment (single dose regimen):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 mL/minute: Administer 1,500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 40 to 59 mL/minute: Administer 750 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 39 mL/minute: Administer 500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Administer 250 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Penciclovir (active metabolite) removed by hemodialysis; administer 250 mg as a single dose after dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recurrent orolabial or genital herpes in HIV-infected patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;40 mL/minute: Administer 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 20 to 39 mL/minute: Administer 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;20 mL/minute: Administer 250 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Penciclovir (active metabolite) removed by hemodialysis; administer 250 mg after each dialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: No dosage adjustment provided in the manufacturer&rsquo;s labeling; has not been studied. However, a 44% decrease in the C<sub>max</sub> of penciclovir (active metabolite) was noted in patients with mild to moderate impairment; impaired conversion of famciclovir to penciclovir may affect efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169817\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Famvir: 125 mg [DSC], 250 mg [DSC], 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169803\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052686\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to meals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3149922\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C  to 30&deg;C (59&deg;F to 86&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052685\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute herpes zoster (shingles); treatment or suppression of recurrent episodes of genital herpes in immunocompetent patients; treatment of recurrent episodes of herpes labialis (cold sores) in immunocompetent patients; treatment of recurrent episodes of oralabial or genital (mucocutaneous) herpes simplex infections in HIV patients (FDA approved in ages &ge;18 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6743664\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Famvir may be confused with Femara</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Famciclovir may be confused with acyclovir</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169882\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fatigue, headache, migraine, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia, neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, anaphylaxis, anemia, angioedema (eyelid edema, facial edema, periorbital edema, pharyngeal edema), cholestatic jaundice, confusion, delirium, disorientation, dizziness, erythema multiforme, hallucination, hypersensitivity angiitis, palpitations, seizure, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169823\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to famciclovir, penciclovir, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169807\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. Acute renal failure has been reported with use of inappropriate high doses in patients with underlying renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lactose: Tablets contain lactose; do not use with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption syndromes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Has not been established for use in initial episodes of genital herpes, recurrent episodes of genital herpes in Black and African-American patients, patients with ophthalmic or disseminated zoster, immunocompromised patients (except HIV-infected patients with orolabial or genital herpes).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299311\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220317\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13294&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus Vaccine: Famciclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of famciclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of famciclovir for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoster Vaccine (Live/Attenuated): Famciclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated).  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169839\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169813\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169827\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Based on available data, use during pregnancy appears to be well tolerated (CDC [Workowski 2015]; HHS [opportunistic; adult] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Health care providers are encouraged to enroll women exposed to famciclovir during pregnancy in the Famvir Pregnancy reporting system (888-669-6682).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052682\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Resolution of rash, renal function, periodic CBC with long-term therapy, liver enzymes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169806\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Famciclovir undergoes rapid biotransformation to the active compound, penciclovir (prodrug), which is phosphorylated by viral thymidine kinase in HSV-1, HSV-2, and VZV-infected cells to a monophosphate form; this is then converted to penciclovir triphosphate and competes with deoxyguanosine triphosphate to inhibit HSV-2 polymerase, therefore, herpes viral DNA synthesis/replication is selectively inhibited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169822\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Food decreases maximum peak penciclovir concentration and delays time to penciclovir peak; AUC remains the same </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Healthy adults: Penciclovir: 1.08 &plusmn; 0.17 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Penciclovir: &lt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Famciclovir is rapidly deacetylated and oxidized to penciclovir (active prodrug); <i>in vitro</i> data demonstrate that metabolism does not occur via CYP isoenzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Penciclovir: 77% &plusmn; 8%  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Penciclovir: 2 to 4 hours; Prolonged in renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 40 to 59 mL/minute: ~3.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 20 to 39 mL/minute: ~6.2 hours, </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;20 mL/minute: ~13.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intracellular penciclovir triphosphate: HSV 1: 10 hours; HSV 2: 20 hours; VZV: 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Penciclovir: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (73% primarily as penciclovir); feces (27%) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169826\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Famciclovir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (30): $174.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $189.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $380.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038615\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bencavir (LU);</li>\n      <li>Ezovir (AU);</li>\n      <li>Famcicool (KR);</li>\n      <li>Famcino (VN);</li>\n      <li>Famcir (KR);</li>\n      <li>Famcler (KR);</li>\n      <li>Famcro (KR);</li>\n      <li>Famicle (KR);</li>\n      <li>Famtrex (IN);</li>\n      <li>Famvir (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, DE, DK, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IE, IL, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LU, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, NZ, PK, PL, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UA, UG, ZA, ZM, ZW);</li>\n      <li>Fanle (CN);</li>\n      <li>Favic (AU);</li>\n      <li>Fenalabial (IE);</li>\n      <li>Herfam (KR);</li>\n      <li>Oravir (FR);</li>\n      <li>Vectavir (LU);</li>\n      <li>Zosfam (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP) Section on Breastfeeding. Breastfeeding and the use of human milk.<i> Pediatrics</i>. 2012;129(3):e827-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-pediatric-drug-information/abstract-text/22371471 /pubmed\" target=\"_blank\" id=\"22371471 \">22371471 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boike SC, Pue MA, and Freed MI, &ldquo;Pharmacokinetics of Famciclovir in Subjects With Varying Degrees of Renal Impairment,&rdquo; <i>Clin Pharmacol Ther</i>, 1994, 55(4):418-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-pediatric-drug-information/abstract-text/8162668/pubmed\" target=\"_blank\" id=\"8162668\">8162668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Famvir tablets (famciclovior) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-pediatric-drug-information/abstract-text/8162668/pubmed\" target=\"_blank\" id=\"8162668\">8162668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. April 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 21, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spruance SL, Bodsworth N, Resnick H, et al, &quot;Single-Dose, Patient-Initiated Famciclovir: A Randomized, Double-Blind, Placebo-Controlled Trial for Episodic Treatment of Herpes Labialis,&quot; <i>J Am Acad Dermatol</i>, 2006, 55(1):47-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-pediatric-drug-information/abstract-text/16781291/pubmed\" target=\"_blank\" id=\"16781291\">16781291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/famciclovir-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13294 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169842\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F169843\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052683\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052677\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169817\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F169803\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052686\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3149922\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052685\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6743664\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169882\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169823\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169807\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299311\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220317\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F169839\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F169813\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F169827\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052682\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169806\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F169822\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F169826\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038615\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13294|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir: Drug information</a></li><li><a href=\"topic.htm?path=famciclovir-patient-drug-information\" class=\"drug drug_patient\">Famciclovir: Patient drug information</a></li></ul></div></div>","javascript":null}